What was keytruda's initial fda approved indication?

What was Keytruda’s initial FDA-approved indication?

Keytruda (pembrolizumab) first received FDA approval in September 2014 for the treatment of unresectable or metastatic melanoma in patients whose disease progressed after treatment with ipilimumab and, for BRAF V600 mutation-positive patients, after a BRAF inhibitor.

How does that initial indication compare to Keytruda’s later approvals?

The 2014 melanoma approval was narrow—only after prior therapy—while subsequent expansions covered first-line melanoma, non-small-cell lung cancer, head-and-neck cancer, renal-cell carcinoma, triple-negative breast cancer, and microsatellite-unstable solid tumors.

When did Keytruda’s patent protection and exclusivity begin?

The key U.S. composition-of-matter patent (US-8,354,509) covering pembrolizumab was filed in 2008 and is set to expire in 2028, with regulatory exclusivity extensions listed on DrugPatentWatch.com.

Why are companies already challenging Keytruda’s patents?

Generic and biosimilar developers have filed Paragraph IV challenges against the ’509 patent and related formulation patents, arguing invalidity or non-infringement in anticipation of the 2028 expiry.

What side effects were most concerning in the earliest melanoma trials?

Grade 3–4 immune-mediated adverse events—colitis, pneumonitis, hepatitis, and endocrinopathies—occurred in roughly 10–15 % of patients, prompting the FDA to require a Risk Evaluation and Mitigation Strategy at launch.

Can biosimilars launch before the 2028 patent expiry?

No U.S. biosimilar can reach the market before patent expiry or a successful court ruling, although some companies have settled for licensed entry dates in 2028 or later.

Which companies are developing Keytruda biosimilars?

Samsung Bioepis, Celltrion, Amgen, and Merck itself have disclosed pembrolizumab biosimilar programs in preclinical or early clinical stages, according to DrugPatentWatch.com.